Cargando…
Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity
BACKGROUND: The role of antibodies in coronavirus disease 2019 (COVID-19) in patients with X-linked agammaglobulinaemia (XLA) has yet to be characterised and clinical courses observed in this cohort of patients have been heterogeneous. Whilst some exhibit spontaneous recovery, others have experience...
Autores principales: | Nguyen, Hanna, Salkeld, Jo, Agarwal, Sangita, Goodman, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373583/ https://www.ncbi.nlm.nih.gov/pubmed/34426799 http://dx.doi.org/10.1016/j.clinpr.2021.100089 |
Ejemplares similares
-
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
por: Weinreich, David M., et al.
Publicado: (2020) -
REGN-EB3: First Approval
por: Markham, Anthony
Publicado: (2021) -
Le régne de l'esprit malin
por: Ramuz, C. F. (Charles Ferdinand), 1878-1947
Publicado: (1946) -
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2023) -
Un « @-CPLF » sous le règne de la COVID-19
por: Schlemmer, F.
Publicado: (2021)